Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, Orzag Predicts

 
• By Jessica Merrill

US antitrust regulators appear poised to take a broader view of disease areas when reviewing mergers, Lazard Freres financial advisory CEO Peter Orszag cautioned.

US M&A scrutiny could be an overhang for pharma • Source: Alamy

More from Pricing Debate

More from Market Access